Key Development
Central Pharmaceutical Joint Stock Company VIDIPHA (HoSE: VDP) has recorded a major restructuring of its shareholder register, coinciding with its public rights offering of nearly 9.94 million common shares to existing shareholders (100:45 subscription ratio) at an issue price of VND 10,000 per share.
Long-standing executive directors and affiliated family members executed a complete equity divestment ($0\%$) alongside the transfer of their prospective share subscription rights, facilitating the entry of two incoming major individual shareholders:
-
Complete Divestment by Legacy Leadership Group (Aug 5 – Aug 20, 2026):
-
Board Chairman Kieu Huu: Sold his entire stake of 1,652,917 shares ($7.5\%$ equity), yielding approximately $\text{VND } 61\text{ billion}$.
-
Ms. Kieu Thuy Mai (Chairman’s Daughter): Divested all 1,377,944 shares ($6.23\%$ equity), valued at $\sim \text{VND } 51\text{ billion}$. (Father and daughter divested $13.7\%$ aggregate equity).
-
Board Member Tran Van Dat & Spouse: Mr. Dat sold nearly 900,000 shares ($4.07\%$), while his spouse Ms. Nguyen Thi Anh Thuy divested 1.02 million shares ($4.61\%$), yielding over $\text{VND } 70\text{ billion}$ combined.
-
Ms. Dinh Thi Hoang Oanh (Spouse of Board Member P. T. Kiet): Liquidated over 2.5 million shares ($11.5\%$ equity).
-
Outcome: Outgoing insiders liquidated nearly 7.5 million VDP shares ($\sim 34\%$ of pre-money charter capital) and declined participation in the capital increase.
-
-
Incoming Institutional-Scale Shareholders:
-
Mr. Le Quang Hai: Acquired over 4.95 million shares on August 7, 2026, elevating his equity holding from $0.087\%$ to nearly 4.97 million shares ($22.5\%$ equity), becoming Vidipha’s largest shareholder.
-
Mr. Nguyen Quoc Hung: Executed a negotiated block purchase of over 2.5 million shares on August 12, 2026 ($\text{VND } 101.5\text{ billion}$), raising his holding from $0\%$ to 11.545% equity.
-
Why It Matters
-
Capitalizing the EU-GMP Cephalosporin Facility: Following the completion of the 9.94 million share rights offering (subscription deadline August 26, 2026), Vidipha’s charter capital will expand from VND 220.8 billion to VND 320.2 billion, raising VND 99.34 billion in gross proceeds.
-
Capital proceeds are earmarked exclusively for constructing a VND 127.8 billion EU-GMP certified Cephalosporin powder-for-injection manufacturing line ($\text{VND } 2\text{B}$ for plant refurbishment across $6,500\text{ m}^2$ and $\text{VND } 97.2\text{B}$ for advanced processing machinery). Residual CapEx will be financed via commercial bank credit facilities.
-
The production facility features a designed nameplate capacity of 10 million vials annually, with execution scheduled from October 2026 through commercial commissioning in January 2028.
-
-
Control Transfer and Strategic Reorientation: The acquisition of over 34% combined equity by Mr. Le Quang Hai and Mr. Nguyen Quoc Hung establishes a consolidated controlling bloc, paving the way for a comprehensive reconstitution of the Board of Directors.
-
Hospital (ETC) Tender Competitiveness: Cephalosporin injectable antibiotics represent high-volume inpatient therapeutics. Obtaining EU-GMP certification is essential for Vidipha to participate in high-margin Group 1 and Group 2 hospital procurement tenders under Ministry of Health bidding frameworks.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the August 25, 2026 equity transactions at Vidipha demonstrate Pharma Ownership Restructuring & EU-GMP CapEx Deployment.
This corporate restructuring involves three strategic drivers:
-
Rights-Offloading Strategy: The outgoing leadership monetized secondary shares at prevailing market prices ($\sim \text{VND } 36,900\text{/share}$) while transferring their VND 10,000 subscription rights, enabling incoming investors to build a controlling equity block at an attractive volume-weighted average cost.
-
Financing High-CapEx Pharmaceutical Modernization: Mid-tier domestic drugmakers (market cap $< \text{VND } 1,000\text{B}$) require institutional capital backing to absorb multi-million dollar EU-GMP facility investments. The incoming equity block provides financial backing through the 2026–2028 construction cycle.
-
M&A and Supply Chain Consolidation: The concentration of >34% equity in two private investors signals a broader strategy to reposition Vidipha’s industrial manufacturing assets within regional pharmaceutical supply chains.
Market Implications
-
Governance Reconstitution at Extraordinary General Meeting (EGM): Vidipha is expected to convene an EGM to elect new Board and Supervisory appointments representing the incoming controlling shareholders.
-
Project Execution Surveillance: Institutional attention will track equipment procurement and cleanroom validation milestones beginning October 2026 ahead of the January 2028 EU-GMP commissioning.
-
Equity Re-Rating Potential: Following capital injection, market valuation will hinge on Vidipha’s execution timeline and subsequent hospital tender market share gains from 2028 onward.
Transaction Summary Matrix: Vidipha Equity & CapEx Profile (August 2026)
| Parameter | Operational Data & Corporate Metrics | Strategic Governance & Market Scope |
| Divesting Leadership Group | Kieu Huu ($7.5\%$), Kieu Thuy Mai ($6.23\%$) | Divested all shares; transferred all subscription rights. |
| Divesting Board Insiders | Tran Van Dat & Spouse ($8.68\%$), P. T. Kiet Spouse ($11.5\%$) | Complete exit from shareholder register. |
| Incoming Major Shareholders | Le Quang Hai ($22.5\%$), Nguyen Quoc Hung ($11.55\%$) | Consolidated controlling bloc holding $\sim 34.05\%$ equity. |
| Capital Rights Offering | 9.94 Million Shares at $\text{VND } 10,000\text{/share}$ | Expands charter capital to VND 320.2 Billion. |
| Capital Allocation Focus | VND 99.3 Billion allocated to Cephalosporin unit | Total project CapEx: VND 127.8 Billion (EU-GMP standard). |
| Plant Capacity & Timeline | 10 Million vials/year | Oct 2026 – Jan 2028 | Targets Group 1 & 2 hospital antibiotic tenders. |